Health Catalyst, Inc. Files Amendment No. 1 to 2023 Annual Report

TL;DR

<b>Health Catalyst, Inc. has filed an amendment to its 2023 annual report, confirming its compliance with SEC filing requirements.</b>

AI Summary

Health Catalyst, Inc. (HCAT) filed a Amended Annual Report (10-K/A) with the SEC on April 23, 2024. Health Catalyst, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and its principal executive offices are located in South Jordan, UT. Health Catalyst's common stock is traded on The Nasdaq Global Select Market under the ticker symbol HCAT. The filing indicates the company has been subject to Section 13 or 15(d) filing requirements for the past 90 days. The company has submitted all required Interactive Data Files electronically for the preceding 12 months.

Why It Matters

For investors and stakeholders tracking Health Catalyst, Inc., this filing contains several important signals. This amendment likely addresses previously disclosed information or provides updated details relevant to the 2023 fiscal year, which could impact investor understanding of the company's financial and operational status. As a large accelerated filer, Health Catalyst's adherence to these reporting standards is crucial for maintaining transparency and investor confidence in the market.

Risk Assessment

Risk Level: low — Health Catalyst, Inc. shows low risk based on this filing. The risk is low as this is an amendment to a standard annual report (10-K/A), indicating a procedural update rather than new negative information.

Analyst Insight

Investors should review the specific changes in Amendment No. 1 to the 10-K filing to understand any updated disclosures or corrections made by Health Catalyst, Inc.

Key Numbers

• 2023 — Fiscal Year End (Fiscal year ended December 31, 2023)
• 001-38993 — Commission File Number (SEC Commission File Number)
• HCAT — Trading Symbol (Common stock trading symbol)
• 2024-04-23 — Filing Date (Date of filing)

Key Players & Entities

• Health Catalyst, Inc. (company) — Registrant name
• 10-K/A (filing) — Form type
• December 31, 2023 (date) — Fiscal year end
• 001-38993 (filing) — Commission file number
• HCAT (ticker) — Trading symbol
• The Nasdaq Global Select Market (exchange) — Name of exchange
• South Jordan, UT (location) — Principal executive offices location
• 20240423 (date) — Filing date

FAQ

Industry Context

Health Catalyst operates in the healthcare technology sector, providing data and analytics solutions to healthcare organizations.

Regulatory Implications

The company is subject to SEC regulations for public companies, including filing annual reports (10-K) and amendments (10-K/A).

What Investors Should Do

1. Review the specific amendments made in the 10-K/A filing.
2. Analyze any updated financial or operational information provided.
3. Assess the impact of these amendments on the company's overall disclosure for fiscal year 2023.

Year-Over-Year Comparison

This is an amendment (10-K/A) to the previously filed 2023 annual report, indicating updates or corrections rather than a new filing.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share HCAT The Nasdaq Global Sele

Filing Documents

• hcat-20231231.htm (10-K/A) — 101KB
• ye2023-10xkaex311xcertific.htm (EX-31.1) — 10KB
• ye2023-10xkaex312xcertific.htm (EX-31.2) — 10KB
• 0001636422-24-000050.txt (&nbsp;) — 314KB
• hcat-20231231.xsd (EX-101.SCH) — 2KB
• hcat-20231231_lab.xml (EX-101.LAB) — 33KB
• hcat-20231231_pre.xml (EX-101.PRE) — 19KB
• hcat-20231231_htm.xml (XML) — 5KB

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules (c) Exhibits See the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. EXHIBIT INDEX Exhibit Number Description of Document Incorporated by Reference from Form Incorporated by Reference from Exhibit Number Date Filed 3.1 Amended and Restated Certificate of Incorporation. S-1/A 3.2 July 12, 2019 3.2 Amended and Restated Bylaws. S-1/A 3.4 July 12, 2019 3.3 Amendment to the Amended and Restated Bylaws 8-K 3.1 August 2, 2021 4.1 Form of common stock certificate. S-1/A 4.1 July 12, 2019 4.2 Fifth Amended and Restated Registration Agreement, dated February 6, 2019, by and among the Registrant and certain of its stockholders. S-1 4.2 June 27, 2019 4.3 Fifth Amended and Restated Investor Rights Agreement, dated February 6, 2019, by and among the Registrant and certain of its stockholders. S-1 4.3 June 27, 2019 4.4 Fifth Amended and Restated Stockholders Agreement, dated February 6, 2019, by and among the Registrant and certain of its stockholders. S-1 4.4 June 27, 2019 4.5 Amendment No. 1 to Financing Documents, dated July 10, 2019, by and among the Registrant and certain of its stockholders. S-1/A 4.5 July 12, 2019 4.6 Description of securities registered under Section 12 of the Exchange Act. 10-K 4.6 February 28, 2020 10.1# Non-Employee Director Compensation Policy. 10-K 10.13 February 22, 2024 10.2# 2019 Stock Option and Incentive Plan, and forms of agreements thereunder. S-1/A 10.12 July 12, 2019 10.3# Amended and Restated 2011 Stock Incentive Plan, and forms of agreements thereunder. S-1 10.13 June 27, 2019 10.4# 2019 Employee Stock Purchase Plan. S-1/A 10.14 July 12, 2019 10.5# Executive Severance Plan. S-1/A 10.16 July 12, 2019 10.6# Offer Letter, dated August 7, 2020, between the Registrant and Kevin Freeman. 10-K 10.6 February 28, 2023 10.7# Offer Letter, dated September 26, 2011, between the Registrant and Daniel Burt

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. HEALTH CATALYST, INC. Date: 4/23/2024 By: /s/ Daniel Burton Daniel Burton Chief Executive Officer (Principal Executive Officer) Date: 4/23/2024 By: /s/ Jason Alger Jason Alger Chief Financial Officer (Principal Financial and Accounting Officer)

View Full Filing

View this 10-K/A filing on SEC EDGAR